Steven Pearson, ICER president (Jeff Rumans)

ICER calls out three drugs from BMS and Lil­ly in re­port on un­sup­port­ed price in­creas­es in Cal­i­for­nia

Drug pric­ing watch­dog ICER on Thurs­day re­leased its fi­nal re­port on drug price in­creas­es in Cal­i­for­nia that were un­sup­port­ed by new clin­i­cal ev­i­dence, point­ing to three out­liers — Bris­tol My­ers Squibb’s can­cer drugs Revlim­id and Spry­cel, and Eli Lil­ly’s mi­graine drug Em­gal­i­ty.

The re­port builds on a price trans­paren­cy law passed in Cal­i­for­nia in 2017, which re­quires man­u­fac­tur­ers to re­port year-over-year spend­ing in­creas­es to pre­scrip­tion drugs’ WAC prices, but does not in­clude net prices, which ICER took is­sue with.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.